Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04656652 · ClinicalTrials.gov registry record · Phase 3
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Daiichi Sankyo.
- Active
- Registry status
- Phase 3
- Development phase
- 605
- Enrollment target
- 20
- Study locations
NCT04656652 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 605 participants, roughly in line with the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 12 states.
The verdict
NCT04656652, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 605 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG DS-1062a
Study Locations (20)
California
- St. Joseph Heritage Healthcare - Anaheim
- The Oncology Institute of Hope and Innovation - Glendale
- University of California San Diego - La Jolla
- UCLA - Los Angeles
- PIH Health - Whittier
Florida
- Memorial Healthcare System- Memorial Cancer Institute - Hollywood
- Orlando Health - Orlando
- Florida Cancer Specialists - Tallahassee
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
New Jersey
- Meridian Hematology and Oncology - Manahawkin
- Astera Cancer Care - Somerset
Arizona
- Ironwood Cancer and Research Center - Chandler
Indiana
- Ft. Wayne Medical Oncology and Hematology - Fort Wayne
Kentucky
- Baptist Health Louisville - Louisville
Louisiana
- Baton Rouge General - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 605 participants |
| Start Date | 2020-12-21 |
| Est. Completion | 2026-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04656652
The ClinicalTrials.gov registry entry for NCT04656652 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 605 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT04656652 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT04656652 about?
NCT04656652 is a clinical study titled "Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)". This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.
What is the current status of trial NCT04656652?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 605 participants. The study started on 2020-12-21. Estimated completion is 2026-01-31.
What conditions does trial NCT04656652 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT04656652?
The interventions under investigation include: Docetaxel (DRUG), DS-1062a (DRUG).
Who is sponsoring clinical trial NCT04656652?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04656652 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.